LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George W. Lemaitre sold 15,000 shares of LeMaitre Vascular stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $37.13, for a total transaction of $556,950.00. Following the transaction, the chief executive officer now owns 3,325,508 shares of the company’s stock, valued at approximately $123,476,112.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

LeMaitre Vascular, Inc. (NASDAQ:LMAT) opened at 36.40 on Friday. The firm has a market cap of $692.40 million, a price-to-earnings ratio of 52.00 and a beta of 0.65. The stock has a 50 day moving average of $32.74 and a 200-day moving average of $28.57. LeMaitre Vascular, Inc. has a 52-week low of $17.70 and a 52-week high of $36.97.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $0.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.17 by $0.06. LeMaitre Vascular had a net margin of 14.19% and a return on equity of 15.02%. The company had revenue of $25.80 million during the quarter, compared to analyst estimates of $25.42 million. During the same quarter last year, the firm posted $0.14 EPS. The business’s revenue for the quarter was up 15.2% on a year-over-year basis. On average, analysts expect that LeMaitre Vascular, Inc. will post $0.80 EPS for the current year.

LeMaitre Vascular announced that its board has approved a share repurchase plan on Thursday, July 27th that permits the company to buyback $7.50 million in shares. This buyback authorization permits the medical instruments supplier to purchase up to 1.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its shares are undervalued.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Wednesday, August 23rd will be paid a dividend of $0.055 per share. This represents a $0.22 dividend on an annualized basis and a yield of 0.60%. The ex-dividend date is Monday, August 21st. LeMaitre Vascular’s dividend payout ratio is presently 31.88%.

TRADEMARK VIOLATION WARNING: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/george-w-lemaitre-sells-15000-shares-of-lemaitre-vascular-inc-lmat-stock/1535513.html.

Hedge funds have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA raised its stake in LeMaitre Vascular by 11,612.5% in the second quarter. BNP Paribas Arbitrage SA now owns 3,748 shares of the medical instruments supplier’s stock worth $117,000 after buying an additional 3,716 shares in the last quarter. Teachers Retirement System of The State of Kentucky purchased a new stake in LeMaitre Vascular during the second quarter worth approximately $137,000. Royce & Associates LP purchased a new stake in LeMaitre Vascular during the second quarter worth approximately $156,000. Royal Bank of Canada raised its stake in LeMaitre Vascular by 856.5% in the second quarter. Royal Bank of Canada now owns 5,031 shares of the medical instruments supplier’s stock worth $157,000 after buying an additional 4,505 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. raised its stake in LeMaitre Vascular by 4,751.1% in the second quarter. Oppenheimer Asset Management Inc. now owns 6,355 shares of the medical instruments supplier’s stock worth $198,000 after buying an additional 6,224 shares in the last quarter. 66.32% of the stock is owned by institutional investors.

A number of brokerages have issued reports on LMAT. Stifel Nicolaus restated a “buy” rating and set a $32.00 target price (up previously from $29.00) on shares of LeMaitre Vascular in a research report on Sunday, July 30th. Benchmark Co. upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Friday, July 28th. BidaskClub cut shares of LeMaitre Vascular from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Craig Hallum began coverage on shares of LeMaitre Vascular in a research report on Tuesday, June 6th. They set a “hold” rating and a $31.00 target price for the company. Finally, Zacks Investment Research cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Tuesday, July 4th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $30.17.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Insider Buying and Selling by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.